Asset Details
Do you wish to reserve the book?
Updated cost comparison of home care subcutaneous versus outpatient intravenous trastuzumab for HER2-positive breast cancer in Singapore
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Updated cost comparison of home care subcutaneous versus outpatient intravenous trastuzumab for HER2-positive breast cancer in Singapore
Do you wish to request the book?
Updated cost comparison of home care subcutaneous versus outpatient intravenous trastuzumab for HER2-positive breast cancer in Singapore
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Updated cost comparison of home care subcutaneous versus outpatient intravenous trastuzumab for HER2-positive breast cancer in Singapore
2026
Overview
With major changes in effective drug prices, we updated our earlier cost-minimization analysis comparing home-based subcutaneous (SC) trastuzumab with outpatient intravenous (IV) trastuzumab for HER2-positive breast cancer in Singapore.
To compare updated annual per-patient costs of home care SC versus outpatient IV trastuzumab.
A cost-minimization analysis was performed.
We conducted a model-based cost-minimization analysis using micro-costing from a societal perspective, incorporating both direct and indirect costs. A Monte Carlo simulation was performed to account for parameter uncertainties.
Annual per-patient cost was S$21,790 (95% uncertainty interval (UI): S$19,662-23,922) for home care versus S$6949 (95% UI: S$5347-10,782) for outpatient care, representing a 214% increase. While service delivery (manpower, facility, consumables) and productivity loss remained cheaper in home care, drug cost is the dominant factor of overall expenditure in trastuzumab delivery.
At current drug prices, outpatient IV trastuzumab administration is the cost-saving option, compared with home care SC trastuzumab.
Publisher
SAGE Publications,SAGE Publishing
Subject
